Axsome Therapeutics Inc (AXSM)
72.50
-1.22
(-1.66%)
USD |
NASDAQ |
May 10, 16:00
72.00
-0.50
(-0.69%)
After-Hours: 19:01
Axsome Therapeutics Cash from Financing (TTM): 278.26M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 278.26M |
December 31, 2023 | 331.01M |
September 30, 2023 | 332.08M |
June 30, 2023 | 475.66M |
March 31, 2023 | 305.04M |
December 31, 2022 | 284.58M |
September 30, 2022 | 284.21M |
June 30, 2022 | 107.70M |
March 31, 2022 | 34.20M |
December 31, 2021 | 11.13M |
September 30, 2021 | 12.53M |
June 30, 2021 | 39.52M |
March 31, 2021 | 49.81M |
December 31, 2020 | 42.41M |
September 30, 2020 | 234.22M |
June 30, 2020 | 207.31M |
March 31, 2020 | 214.86M |
Date | Value |
---|---|
December 31, 2019 | 252.39M |
September 30, 2019 | 67.04M |
June 30, 2019 | 67.31M |
March 31, 2019 | 48.88M |
December 31, 2018 | 10.03M |
September 30, 2018 | 10.13M |
June 30, 2018 | 9.471M |
March 31, 2018 | 8.150M |
December 31, 2017 | 23.88M |
September 30, 2017 | 25.20M |
June 30, 2017 | 25.08M |
March 31, 2017 | 25.01M |
December 31, 2016 | |
September 30, 2016 | |
June 30, 2016 | |
March 31, 2016 | |
December 31, 2015 | 52.88M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
11.13M
Minimum
Dec 2021
475.66M
Maximum
Jun 2023
181.56M
Average
211.09M
Median
Cash from Financing (TTM) Benchmarks
Krystal Biotech Inc | 211.86M |
Amgen Inc | -2.169B |
Vertex Pharmaceuticals Inc | -625.00M |
Alnylam Pharmaceuticals Inc | 154.67M |
Catalyst Pharmaceuticals Inc | 130.04M |